House of Hyperbaric Logo (1)
Join The Registry

Clinical Indications for Hyperbaric Oxygen Therapy

Hyperbaric Oxygen Therapy for Clostridial Myositis and Myonecrosis (Gas Gangrene)

Clostridial myositis and myonecrosis, commonly called gas gangrene, is a rapidly progressive and potentially fatal infection of skeletal muscle characterized by extensive tissue destruction, toxin production, systemic toxicity, and variable gas formation within affected tissues.

Hyperbaric Oxygen Therapy (HBOT) is recognized by the Undersea & Hyperbaric Medical Society (UHMS) as an accepted indication for clostridial myositis and myonecrosis. When incorporated into treatment, HBOT is used as an adjunct to—not a replacement for—urgent surgical management, antimicrobial therapy, resuscitation, and critical care.

Gas gangrene is a surgical emergency. Evaluation for hyperbaric treatment should never delay appropriate resuscitation, antibiotic administration, surgical consultation, or operative source control.

Clostridial myonecrosis can progress extraordinarily rapidly.

Early recognition and immediate multidisciplinary management are essential because toxin production, tissue necrosis, hemolysis, shock, renal injury, and multiorgan failure may develop over a short period of time.

When the diagnosis is suspected, management should proceed urgently and may involve:

  • Immediate surgical consultation
  • Resuscitation and hemodynamic stabilization
  • Broad-spectrum antimicrobial therapy
  • Urgent surgical exploration and debridement
  • Microbiologic evaluation
  • Critical care support
  • Early hyperbaric medicine consultation when HBOT is being considered

Transfer to a hyperbaric facility should be coordinated carefully and should not postpone time-critical operative management.

Clinical Presentation

Severe and rapidly increasing pain is often an early clinical feature of clostridial myonecrosis. The degree of pain may initially appear disproportionate to the visible wound or skin findings.

Clinical features may include:

  • Sudden or rapidly increasing pain
  • Progressive swelling and tense edema
  • Tenderness extending beyond the apparent wound
  • Pale skin progressing to dusky, bronze, purple, or dark discoloration
  • Hemorrhagic bullae
  • Thin or serosanguineous wound drainage
  • Crepitus
  • Gas within soft tissues on imaging
  • Tachycardia
  • Fever
  • Hypotension
  • Hemolysis
  • Hemoglobinuria
  • Renal dysfunction
  • Altered mental status
  • Shock and multiorgan failure
Systemic toxicity may progress rapidly. Importantly, clinicians should not wait for dramatic skin changes, crepitus, or extensive radiographic gas before initiating surgical evaluation when the clinical picture is concerning.

Diagnosis

The diagnosis of clostridial myonecrosis is primarily clinical and should be treated as an emergency when strongly suspected. Surgical exploration plays both a diagnostic and therapeutic role. Gram stain and cultures of involved tissue or wound fluid can help identify clostridial organisms and distinguish monomicrobial clostridial infection from polymicrobial necrotizing infection. Because several organisms can produce gas within soft tissues, the presence of tissue gas alone does not establish a diagnosis of clostridial myonecrosis. Imaging may help identify soft-tissue gas or define the extent of disease in selected circumstances, but diagnostic imaging should not delay operative exploration when clinical suspicion for a rapidly progressive necrotizing infection is high.

Why Hyperbaric Oxygen Therapy Is Used

When HBOT is incorporated into treatment for clostridial myonecrosis, several physiologic mechanisms provide the rationale for its use.

Inhibition of Clostridial Growth and Toxin Production

Clostridial organisms proliferate most effectively in low-oxygen environments. Hyperbaric oxygen produces tissue oxygen tensions substantially higher than can be achieved under normal atmospheric conditions. Experimental evidence demonstrates that sufficiently elevated tissue oxygen tensions can inhibit the growth of C. perfringens and suppress production of alpha toxin, an important mediator of tissue destruction and systemic toxicity.

Increased Oxygenation of Threatened Tissue

Edema, thrombosis, toxin-mediated vascular injury, and impaired perfusion can produce severe tissue hypoxia around the infected area. HBOT substantially increases dissolved oxygen within plasma, allowing oxygen delivery to compromised tissues despite impaired local circulation.

Support of Host Defense

Neutrophil-mediated bacterial killing is oxygen dependent. Increasing tissue oxygen tensions may improve leukocyte function within hypoxic but potentially viable tissue and support the patient's endogenous antimicrobial defenses.

Reduction of Edema

Hyperbaric oxygen can produce vasoconstriction while maintaining increased tissue oxygen delivery. This may help reduce edema in injured tissue and potentially improve microvascular conditions surrounding the affected area.

Tissue Preservation

One proposed advantage of adjunctive HBOT is the ability to support marginally viable tissue while the progression of infection is controlled. This may assist clinicians in distinguishing irreversibly necrotic tissue from tissue that may remain salvageable, although surgical decisions must always be based on the patient's overall clinical status and operative findings.

HBOT Does Not Replace Surgical Source Control

This distinction is critical. Clostridial myonecrosis requires urgent surgical evaluation. Necrotic tissue provides an environment in which infection and toxin production can continue. Surgical exploration and debridement therefore remain fundamental components of treatment. HBOT cannot remove necrotic tissue, drain infected compartments, correct major vascular disruption, or substitute for definitive source control. Likewise, HBOT should not delay: Emergency surgical consultation Operative exploration Debridement of clearly necrotic tissue Antibiotic administration Resuscitation Hemodynamic support Other lifesaving interventions When HBOT is available and selected as part of management, treatment requires close coordination among surgery, infectious disease, emergency medicine, critical care, and hyperbaric medicine teams.

Antimicrobial Therapy

Antimicrobial treatment should be initiated promptly. Because gas within tissue can result from organisms other than clostridia and necrotizing infections may be polymicrobial, broad-spectrum antimicrobial therapy is generally required initially while the causative organism is being determined. Once clostridial myonecrosis is established, antimicrobial therapy can be adjusted according to the organism, susceptibility information, clinical circumstances, and institutional protocols. Infectious Diseases Society of America guidance recommends penicillin plus clindamycin as definitive antimicrobial treatment for documented clostridial myonecrosis. Clindamycin and other protein-synthesis-inhibiting antimicrobial agents are of particular interest in toxin-mediated infections because suppression of bacterial protein synthesis may reduce toxin production. Antimicrobial selection and dosing should be directed by the treating clinical team and adjusted according to microbiologic results and patient-specific factors.

When Should Hyperbaric Consultation Be Considered?

Early hyperbaric medicine consultation may be appropriate when there is a confirmed or strongly suspected diagnosis of:

  • Clostridial myositis
  • Clostridial myonecrosis
  • Gas gangrene
  • Spreading clostridial cellulitis accompanied by systemic toxicity

Consultation is particularly relevant when a hospital has rapid access to a hyperbaric facility capable of treating critically ill patients without delaying essential surgical management.

The decision to incorporate HBOT should consider:

  • Clinical severity
  • Rate of infection progression
  • Hemodynamic stability
  • Surgical findings
  • Extent of tissue involvement
  • Availability of an appropriate chamber
  • Critical-care capabilities of the hyperbaric facility
  • Transportation requirements
  • Whether HBOT can be provided without delaying source control

Timing of HBOT

If HBOT is selected as part of treatment, hyperbaric-medicine guidance emphasizes early initiation.

The rationale is to rapidly increase tissue oxygen tension and suppress continued toxin production while antibiotics, surgery, and host defenses address the infection.

Treatment schedules are determined by the hyperbaric physician based on clinical severity, progression of infection, operative findings, response to treatment, and facility protocols.

Repeated treatments may be used during the early phase of management when clinically appropriate.

However, there is no circumstance in which waiting for hyperbaric treatment should supersede necessary resuscitation or urgent surgical intervention.

HBOT as Part of Multidisciplinary Care

Clostridial myonecrosis frequently requires coordinated care across several specialties.

Treatment may involve:

  • Emergency medicine
  • General, orthopedic, vascular, or trauma surgery
  • Infectious disease
  • Critical care
  • Hyperbaric medicine
  • Wound care
  • Reconstructive surgery
  • Rehabilitation

Patients may require repeated operative debridement, intensive hemodynamic support, management of hemolysis or renal dysfunction, reconstruction of resulting tissue defects, and prolonged rehabilitation after the acute infection has been controlled.

HBOT, when utilized, represents one component of this broader treatment strategy.

Clinical Evidence and Guidelines

Clostridial myositis and myonecrosis is recognized by the Undersea & Hyperbaric Medical Society as an accepted indication for Hyperbaric Oxygen Therapy.

UHMS describes treatment using a combined approach of HBOT, surgery, and antibiotics. The physiologic rationale for HBOT includes inhibition of clostridial growth and toxin production, improved oxygenation of ischemic tissue, and support of host antimicrobial defenses.

The clinical evidence base, however, has important limitations.

Because gas gangrene is uncommon, rapidly progressive, heterogeneous, and requires immediate treatment, high-quality randomized clinical trials are extremely difficult to perform. Much of the evidence supporting HBOT comes from experimental studies, observational clinical series, retrospective experience, and expert consensus.

The Infectious Diseases Society of America takes a more conservative position. Its skin and soft-tissue infection guideline strongly recommends urgent surgical exploration and debridement and appropriate antimicrobial therapy but does not recommend routine HBOT because clinical benefit has not been established in high-quality studies and because transfer for HBOT could delay resuscitation or surgery.

These positions are not entirely contradictory regarding the central priority of treatment: rapid surgical assessment, source control, antimicrobial therapy, and resuscitation are essential.

For centers incorporating HBOT, treatment should therefore be viewed as an adjunct that must be integrated into emergency management without delaying definitive surgical care.

Medicare Coverage

Gas gangrene is specifically listed as a covered condition under the Centers for Medicare & Medicaid Services National Coverage Determination for Hyperbaric Oxygen Therapy (NCD 20.29).

Medicare recognition of gas gangrene as a covered HBOT indication does not establish that treatment is appropriate for every individual patient.

Coverage and payment remain subject to applicable medical necessity, documentation, coding, facility, and payer requirements.

When to Refer

Consider early hyperbaric medicine consultation when clostridial myonecrosis or gas gangrene is confirmed or strongly suspected and HBOT can be incorporated without interfering with emergent surgical care.

Clinical features that should heighten concern include:

  • Severe pain disproportionate to initial examination
  • Rapidly progressive soft-tissue swelling
  • Skin discoloration or hemorrhagic bullae
  • Crepitus or soft-tissue gas
  • Systemic toxicity
  • Hemolysis
  • Rapid hemodynamic deterioration
  • Evidence of muscle necrosis
  • Gram-positive rods identified from affected tissue in the appropriate clinical setting

Do not delay surgical exploration, antimicrobial therapy, or resuscitation while arranging hyperbaric treatment.

Early communication among the surgical and hyperbaric teams can determine whether HBOT can be incorporated safely into the patient’s overall treatment plan.

Advance Your Hyperbaric Medicine Training

Webcme logo

Explore Hyperbaric Medicine: Principles & Practice, 2nd Edition, a comprehensive 40-hour CME/CEU course designed for physicians, advanced practice providers, nurses, and allied health professionals seeking deeper clinical and operational knowledge in hyperbaric medicine.

View the Course

References